Luminex won clearance from the FDA and European CE-IVD mark of approval to introduce its ARIES M1 real-time PCR system. Designed for smaller clinical labs, the M1 is a lower throughput version of the company’s ARIES system, offering essentially the same features in a smaller package.
It can run six samples and up to six different assays simultaneously, extracting, amplifying, and detecting genetic material all on its own once the cartridges are loaded.
“In developing the ARIES family of systems, we listened closely to the needs of our customers and crafted these products to increase laboratory efficiency, ensure result accuracy, and fit seamlessly into today’s lean laboratory. We are now adding another system based on customer feedback, and in doing so, expanding our market reach,” said Homi Shamir, President and CEO of Luminex in a statement. “Luminex now has the broadest offering of low-plex and high-plex sample to answer systems for clinical laboratories performing molecular diagnostic testing. And, with the acquisition of NSPH behind us, we can focus on continuing to move products in our pipeline towards commercialization and realizing the value in our newly acquired asset.”